{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T01:20:05Z","timestamp":1792545605181,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100030732","name":"MSD","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030732","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.annonc.2025.11.013","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T22:01:37Z","timestamp":1763762497000},"page":"378-387","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Sacituzumab tirumotecan in participants with advanced or metastatic urothelial carcinoma and disease progression after chemotherapy and immune checkpoint inhibitors"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7950-6669","authenticated-orcid":false,"given":"Y.","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Seneviratne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1264-129X","authenticated-orcid":false,"given":"G.","family":"Blumenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Akala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.annonc.2025.11.013_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"2","key":"10.1016\/j.annonc.2025.11.013_bib3","doi-asserted-by":"crossref","first-page":"e34","DOI":"10.1016\/j.eururo.2024.06.023","article-title":"Membranous expression of target protein is required for ADC response in urothelial cancer","volume":"87","author":"Kl\u00fcmper","year":"2025","journal-title":"Eur Urol"},{"key":"10.1016\/j.annonc.2025.11.013_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.858865","article-title":"Head-to-head comparison of the expression differences of NECTIN-4, TROP-2, and HER2 in urothelial carcinoma and its histologic variants","volume":"12","author":"Fan","year":"2022","journal-title":"Front Oncol"},{"issue":"3-4","key":"10.1016\/j.annonc.2025.11.013_bib5","doi-asserted-by":"crossref","first-page":"84","DOI":"10.18632\/genesandcancer.40","article-title":"Trop2 and its overexpression in cancers: regulation and clinical\/therapeutic implications","volume":"6","author":"Shvartsur","year":"2015","journal-title":"Genes Cancer"},{"issue":"48","key":"10.1016\/j.annonc.2025.11.013_bib6","doi-asserted-by":"crossref","first-page":"28989","DOI":"10.18632\/oncotarget.25615","article-title":"The emergence of trophoblast cell-surface antigen 2 (TROP-2) as a novel cancer target","volume":"9","author":"Goldenberg","year":"2018","journal-title":"Oncotarget"},{"issue":"22","key":"10.1016\/j.annonc.2025.11.013_bib7","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2025.11.013_bib8","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.951589","article-title":"Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132","volume":"12","author":"Cheng","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.11.013_bib9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13045-025-01705-2","article-title":"Results of a phase 1\/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies","volume":"18","author":"Ouyang","year":"2025","journal-title":"J Hematol Oncol"},{"issue":"suppl 7","key":"10.1016\/j.annonc.2025.11.013_bib10","doi-asserted-by":"crossref","first-page":"CT247","DOI":"10.1158\/1538-7445.AM2024-CT247","article-title":"Abstract CT247: Updated efficacy and safety of anti-TROP2 ADC SKB264 (MK-2870) for previously treated advanced NSCLC in phase 2 study","volume":"84","author":"Fang","year":"2024","journal-title":"Cancer Res"},{"issue":"suppl 7","key":"10.1016\/j.annonc.2025.11.013_bib11","article-title":"Abstract CT038: Preliminary efficacy and safety results of anti-TROP2 ADC SKB264 (MK-2870) in patients (pts) with previously treated advanced gastric (G) or gastroesophageal junction (GEJ) cancer from a phase 2 study","volume":"84","author":"Rodon","year":"2024","journal-title":"Cancer Res"},{"issue":"suppl 2","key":"10.1016\/j.annonc.2025.11.013_bib12","first-page":"S544","article-title":"715MO \u2013 Safety and efficacy of sacituzumab tirumotecan (sac-TMT) in patients (pts) with previously treated advanced endometrial carcinoma (EC) and ovarian cancer (OC) from a phase II study","volume":"35","author":"Wang","year":"2024","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2025.11.013_bib13","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.annonc.2025.11.013_bib14","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1038\/s41591-025-03630-w","article-title":"Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial","volume":"31","author":"Yin","year":"2025","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.annonc.2025.11.013_bib15","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1200\/JCO.2009.25.4599","article-title":"Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens","volume":"28","author":"Bellmunt","year":"2010","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2025.11.013_bib16","doi-asserted-by":"crossref","first-page":"1976","DOI":"10.1038\/s41591-025-03638-2","article-title":"Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1\/2 and phase 2 trials","volume":"31","author":"Zhao","year":"2025","journal-title":"Nat Med"},{"issue":"5","key":"10.1016\/j.annonc.2025.11.013_bib17","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.annonc.2025.01.011","article-title":"Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann Oncol"},{"key":"10.1016\/j.annonc.2025.11.013_bib18","series-title":"Full prescribing information","year":"2024"},{"key":"10.1016\/j.annonc.2025.11.013_bib19","series-title":"Full prescribing information","year":"2025"},{"issue":"suppl 5","key":"10.1016\/j.annonc.2025.11.013_bib20","article-title":"Datopotamab deruxtecan (Dato-DXd) in locally advanced\/metastatic urothelial cancer: updated results from the phase 1 TROPIONPanTumor01 study","volume":"43","author":"Meric-Bernstam","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.annonc.2025.11.013_bib21","article-title":"Genomic landscape and clinical relevance in Chinese patients with upper tract urothelial carcinoma","volume":"9","author":"Shang","year":"2025","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.11.013_bib22","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.annonc.2023.09.3114","article-title":"The Double Antibody Drug Conjugate (DAD) phase I trial: sacituzumab govitecan plus enfortumab vedotin for metastatic urothelial carcinoma","volume":"35","author":"McGregor","year":"2024","journal-title":"Ann Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425062726?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425062726?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T20:59:24Z","timestamp":1777582764000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753425062726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":21,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["S0923753425062726"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2025.11.013","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sacituzumab tirumotecan in participants with advanced or metastatic urothelial carcinoma and disease progression after chemotherapy and immune checkpoint inhibitors","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2025.11.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s) and Merck & Co., Inc., Rahway, NJ, USA and its affiliates. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}